A double-blind, randomised, placebo-controlled trial to study the anti-tumour effects of 250 mg FASLODEX (fulvestrant) in oestrogen receptor-positive primary breast cancers in premenopausal women

Study identifier:9238IL/0041

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomised, placebo-controlled trial to study the anti-tumour effects of 250 mg FASLODEX (fulvestrant) in oestrogen receptor-positive primary breast cancers in premenopausal women

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria